GHK-Cu dosage

GHK-Cu topical dosage

Reported topical GHK-Cu routines use 1–3% formulations applied once or twice daily for 8–12 weeks.[18]

GHK-Cu is a copper-binding signal peptide involved in collagen and extracellular-matrix turnover. Topical formulations may support skin texture and appearance.[1][2][3][4][5][6][7][8][18]

GHK-Cu injectable dosage

Reported injectable protocols use 1–2 mg per administration, 1-2 times daily for 4-12 weeks. An alternative reported subcutaneous schedule steps from 1 mg in weeks 1–4 to 1.5 mg in weeks 5–8 and 2 mg from week 9, on three or five days per week, over 8–12 weeks.[2][11][9][19]

Injectable GHK-Cu produces systemic exposure to a copper-binding peptide. The skin-appearance findings for topical cosmetics do not establish the effects of systemic administration.[11][5][6][7][2][8]

GHK-Cu transdermal — ex vivo microneedles dosage

The microneedle experiment places 2 mL of 5.8 mM (GHK)₂Cu solution over a 1 cm² excised-skin sample, with human-skin permeation measured over 9 hours. The starting complex has a 2:1 GHK-to-copper molar ratio. This is the donor solution placed above the skin, not the amount absorbed or a patient patch dose.[10]

Transdermal GHK-Cu depends on its carrier and delivery system. A consistent absorbed amount or systemic treatment effect has not been established for these preparations.[10][5][6][7][2][8]

Frequency and timing

Topical products are applied in the morning or evening; injection timing follows a consistent morning or evening schedule. Experimental transdermal preparations follow their own application and observation periods.[9][11][18][2][10]

Cycle length and breaks

Topical: 8–12 wk. Injectable: 4-12 weeks. Transdermal — ex vivo microneedles: 9-hour human-skin experiment. A standard break interval between courses is not established.[18][2][11][9][10]

Approval and product quality

GHK-Cu is not an FDA-approved drug.[16][17][1]

Side effects and long-term safety

For topical GHK-Cu, local irritation, stinging, redness, itching and sensitivity are the main tolerability concerns. Vehicle, pH, delivery method, copper loading and peptide content can change tolerability and performance. Injectable or systemic exposure adds concerns about aggregation, impurities, immunogenicity and product quality. Long-term injectable safety, human dose-ranging and route-specific interactions remain uncertain.[9][10][11][3][1][4][12]

Route-specific dosing limits

Systemic exposure deserves extra caution in copper-handling disorders such as Wilson disease, where copper accumulates in the body. Additional schedules attributed to Everything Peptide are reported patterns; citing research does not make these schedules clinically established or approved product instructions.[12][11][19]